Pharmaceutical Contract Development & Manufacturing Market by Service (Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services), End User (Big Pharma, Generic Pharmaceutical Companies, Small & Mid-Size Pharma) -

Pharmaceutical Contract Development & Manufacturing Market by Service (Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services), End User (Big Pharma, Generic Pharmaceutical Companies, Small & Mid-Size Pharma) - Global Forecast 2024-2030


The Pharmaceutical Contract Development & Manufacturing Market size was estimated at USD 125.73 billion in 2023 and expected to reach USD 136.27 billion in 2024, at a CAGR 8.46% to reach USD 222.04 billion by 2030.

Pharmaceutical contract development and manufacturing (CDMO) refers to outsourcing drug development and manufacturing processes to third-party organizations. CDMO services cover a broad range of activities, including drug discovery, formulation development, process optimization, scale-up, regulatory submission support, and the eventual manufacturing of the final product for clinical trials or commercial distribution. Pharmaceutical companies can concentrate on their core competencies, such as drug discovery and marketing, by outsourcing to CDMOs while gaining access to cutting-edge technologies and regulatory expertise. The applications for contract development and manufacturing span the entire lifecycle of pharmaceutical products. The increasing trend of pharmaceutical outsourcing due to cost reduction and efficiency gains and expanding pipelines of biopharmaceutical companies requiring specialized manufacturing capabilities have increased the demand for pharmaceutical contract development and manufacturing. In addition, the globalization of the pharmaceutical industry drives the need for local manufacturing facilities to navigate regulatory landscapes, developing a growing need for pharmaceutical contract development and manufacturing services. However, regulatory challenges and compliance costs associated with varying international standards and complexities in supply chain management and logistics can negatively affect the pharmaceutical contract development and manufacturing market. Nevertheless, the emergence of personalized medicine and next-generation therapies creates opportunities for pharmaceutical contract development and manufacturing. Moreover, investments by vendors in advanced manufacturing technologies such as continuous manufacturing and single-use systems are expected to make pharmaceutical contract development and manufacturing an attractive option for end-users.

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Demand for Generics and Biological Therapies
5.1.1.2. Increasing Investments in Pharmaceutical R&D
5.1.1.3. Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
5.1.2. Restraints
5.1.2.1. Introduction of Serialization
5.1.3. Opportunities
5.1.3.1. Increasing Focus on Nuclear Medicine and Specialty Drugs
5.1.3.2. Growing need for Cell and Gene Therapies
5.1.4. Challenges
5.1.4.1. Variable Trade Policies Between Countries
5.2. Market Segmentation Analysis
5.2.1. Service: Rising penetration of biologics manufacturing services by end-users to adhere to stringent regulatory standards
5.2.2. End User: Big pharma companies widely adopting pharmaceutical CDMO services to manage complex drug development
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
5.9.1. Increasing CDMO Manufacturing Footprint in Asian Countries
5.9.2. CDMO Industry Consolidation
5.9.3. Increasing Outsourcing of Clinical Trials to Emerging Markets
6. Pharmaceutical Contract Development & Manufacturing Market, by Service
6.1. Introduction
6.2. Biologics Manufacturing Services
6.3. Drug Development Services
6.4. Pharmaceutical Manufacturing Services
6.5. Secondary Packaging Services
7. Pharmaceutical Contract Development & Manufacturing Market, by End User
7.1. Introduction
7.2. Big Pharma
7.3. Generic Pharmaceutical Companies
7.4. Small & Mid-Size Pharma
8. Americas Pharmaceutical Contract Development & Manufacturing Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Pharmaceutical Contract Development & Manufacturing Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Pharmaceutical Contract Development & Manufacturing Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Alcami Announces Acquisition of West-Coast-Based Pacific Pharmaceutical Services
11.3.2. Piramal Pharma to Invest INR 1,000 Crore for Expansion
11.3.3. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
FIGURE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET DYNAMICS
FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings